FDA Would Establish Conditions For Swift Manufacturing Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft 'conditions established' guidance proposes to smooth the way for continual improvement of manufacturing processes for drugs and biologics by saying which manufacturing changes don't need to be reported.
You may also be interested in...
FDA Opens Door To Enhanced Applications For Quicker CMC Reviews
US FDA hopes to expedite NDA and ANDA reviews and lay groundwork for eventual ICH adoption by asking sponsors to make better use of CTD's Quality Overall Summary, which could allow agency reviewers to focus on patient impact and other key factors.
ICH Seeks To Resolve Impasse Over Q12 Legal Review This Week
It remains uncertain whether a legal review by the European Commission that since June has delayed public consultation of draft ICH Q12 post-approval changes guideline can be resolved during this week's ICH meeting in Geneva.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.